Harvard Bioscience (NASDAQ:HBIO) Director William Snider Acquires 12,525 Shares

Harvard Bioscience, Inc. (NASDAQ:HBIO) Director William Snider bought 12,525 shares of the stock in a transaction that occurred on Monday, March 16th. The stock was acquired at an average price of $4.99 per share, for a total transaction of $62,499.75. Following the completion of the transaction, the director owned 23,525 shares in the company, valued at $117,389.75. This trade represents a 113.86% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

William Snider also recently made the following trade(s):

• On Tuesday, March 17th, William Snider purchased 8,475 shares of Harvard Bioscience stock. The shares were acquired at an average price of $4.85 per share, with a total value of $41,103.75.

Harvard Bioscience Trading Down 2.8%

NASDAQ:HBIO opened at $4.87 on Wednesday. Harvard Bioscience, Inc. has a 1 year low of $2.81 and a 1 year high of $9.50. The stock has a market cap of $217.79 million, a price-to-earnings ratio of -0.38 and a beta of 1.51. The business has a fifty day moving average of $5.63 and a 200-day moving average of $5.66. The company has a debt-to-equity ratio of 2.61, a quick ratio of 0.41 and a current ratio of 2.20.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Bank of America Corp DE boosted its position in shares of Harvard Bioscience by 44.4% in the fourth quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock worth $82,000 after buying an additional 11,948 shares during the period. Geode Capital Management LLC raised its position in Harvard Bioscience by 4.3% during the fourth quarter. Geode Capital Management LLC now owns 460,793 shares of the medical instruments supplier’s stock valued at $308,000 after buying an additional 18,923 shares during the period. Legato Capital Management LLC raised its position in Harvard Bioscience by 210.4% during the fourth quarter. Legato Capital Management LLC now owns 43,467 shares of the medical instruments supplier’s stock valued at $29,000 after buying an additional 29,462 shares during the period. Goldman Sachs Group Inc. lifted its stake in Harvard Bioscience by 291.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 49,751 shares of the medical instruments supplier’s stock worth $33,000 after acquiring an additional 37,057 shares in the last quarter. Finally, XTX Topco Ltd purchased a new stake in Harvard Bioscience in the 4th quarter worth about $26,000. Institutional investors own 80.87% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on HBIO shares. Benchmark lowered their target price on shares of Harvard Bioscience from $20.00 to $6.00 and set a “speculative buy” rating on the stock in a research note on Friday, March 13th. Zacks Research raised shares of Harvard Bioscience to a “hold” rating in a research note on Thursday, December 11th. New Street Research set a $6.00 price objective on shares of Harvard Bioscience in a report on Friday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Harvard Bioscience in a research note on Monday, December 29th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $6.00.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.